Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M603Revenue $M25.1Net Margin (%)-1,069.4Z-Score-8.9
Enterprise Value $M821EPS $-1.4Operating Margin %-893.9F-Score2
P/E(ttm))0Cash Flow Per Share $0.7Pre-tax Margin (%)-1,070.1Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %0Quick Ratio1.0Cash flow > EarningsY
Price/Sales23.75-y EBITDA Growth Rate %0Current Ratio1.0Lower Leverage y-yN
Price/Cash Flow6.3y-y EBITDA Growth Rate %0ROA % (ttm)-62.4Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M196ROI % (ttm)-57.3Gross Margin Increase y-yN

Gurus Latest Trades with EXEL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
EXELJean-Marie Eveillard 2014-06-30 Sold Out $3.22 - $3.8
($3.45)
$ 3.08-12%Sold Out0
EXELJean-Marie Eveillard 2014-03-31 Reduce-0.01%$3.38 - $8.24
($6.84)
$ 3.08-122%Reduce -65.91%400,000
EXELJean-Marie Eveillard 2012-09-30 Add0.02%$4.28 - $6.45
($5.29)
$ 3.08-72%Add 422.58%1,175,800
EXELJean-Marie Eveillard 2012-03-31 Add$4.49 - $6.47
($5.14)
$ 3.08-67%Add 125.00%225,000
EXELJean-Marie Eveillard 2011-12-31 Buy $3.95 - $7.81
($5.01)
$ 3.08-63%New holding100,000
EXELCarl Icahn 2011-09-30 Sold Out -0.43%$5.5 - $9.22
($7.34)
$ 3.08-138%Sold Out0
EXELJean-Marie Eveillard 2011-03-31 Sold Out $7.22 - $12.45
($9.89)
$ 3.08-221%Sold Out0
EXELJean-Marie Eveillard 2010-12-31 Buy 0.01%$3.98 - $9.08
($5.66)
$ 3.08-84%New holding280,000
EXELJean-Marie Eveillard 2009-12-31 Sold Out -0.02%$5.33 - $8
($6.86)
$ 3.08-123%Sold Out0
EXELJean-Marie Eveillard 2009-09-30 Buy 0.02%$4.4 - $6.99
($5.65)
$ 3.08-83%New holding274,700
EXELJean-Marie Eveillard 2009-06-30 Sold Out -0.01%$4.16 - $5.55
($4.88)
$ 3.08-58%Sold Out0
EXELJean-Marie Eveillard 2009-03-31 Reduce$4.32 - $5.85
($4.8)
$ 3.08-56%Reduce -25.67%144,800
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

EXEL is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


EXEL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MARCHESI VINCENT TDirector 2014-09-17Buy20,000$1.7180.12 view
WILLSEY LANCEDirector 2013-08-29Buy10,000$5.15-40.19 view
MARCHESI VINCENT TDirector 2012-12-20Buy4,000$4.68-34.19 view
MARCHESI VINCENT TDirector 2012-12-19Buy6,000$4.72-34.75 view
Schwab GiselaEVP and Chief Medical Officer 2012-12-10Buy25,000$4.39-29.84 view
MARCHESI VINCENT TDirector 2012-06-14Sell7,000$5.13-39.96 view
RIVERA LUPE MEVP, Operations 2010-12-17Sell29,427$8.5-63.76 view
RIVERA LUPE MEVP, Operations 2010-12-15Sell75,000$7.5-58.93 view
Schwab GiselaEVP & Chief Medical Officer 2010-12-09Sell4,112$6.5-52.62 view
WILLSEY LANCEDirector 2010-09-07Buy36,200$3.6-14.44 view

Press Releases about EXEL :

    Quarterly/Annual Reports about EXEL:

    News about EXEL:

    Articles On GuruFocus.com
    5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic Communications Inc, and Aeropostale I Dec 28 2014 
    5-year lows: National Presto Industries, Ennis Inc, Landauer Inc, and Exelixis Inc. Sep 28 2014 
    Weekly 3-Year Low Highlights: UAN, CLD, EXEL, QNST Sep 06 2014 
    Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian Trust, Millennial Media Inc., Exelix May 05 2014 
    5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
    Exelixis Inc. Reports Operating Results (10-K) Feb 22 2011 
    Exelixis Inc. (EXEL) CFO Frank Karbe buys 16,500 Shares Aug 25 2010 
    Exelixis Inc. Reports Operating Results (10-Q) Aug 05 2010 
    Exelixis Inc. Reports Operating Results (10-Q) May 11 2010 
    Exelixis Announces Second Quarter 2009 Financial Results Jul 30 2009 


    More From Other Websites
    Biotech Investors: May 29th Could Be A Big Day Apr 21 2015
    Exelixis (EXEL) Shares March Higher, Can It Continue? - Tale of the Tape Apr 20 2015
    The Zacks Analyst Blog Highlights: Rigel Pharmaceuticals, Exelixis and Atlas Resource Partners -... Apr 20 2015
    Why Exelixis (EXEL) Stock Might be a Great Pick - Tale of the Tape Apr 20 2015
    3 Momentum Picks Under $10 to Sail the Turbulent Market - Analyst Blog Apr 17 2015
    Exelexis (EXEL) Is The 'Chart of the Day' Apr 16 2015
    Bulls can't get enough of Exelixis Apr 13 2015
    Exelixis' Cometriq Gets Fast Track Status in U.S. - Analyst Blog Apr 10 2015
    Exelixis to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015 Apr 09 2015
    Exelixis to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015 Apr 09 2015
    Exelixis (EXEL) Stock Rises Today Following FDA Fast Track Designation Apr 09 2015
    Exelixis’ Cabozantinib Granted Fast Track Designation by FDA For Advanced Renal Cell Carcinoma Apr 09 2015
    Exelixis’ Cabozantinib Granted Fast Track Designation by FDA For Advanced Renal Cell Carcinoma Apr 09 2015
    Roche open to alliances in hunt for cancer drug combinations Apr 01 2015
    Roche open to alliances in hunt for cancer drug combinations Apr 01 2015
    Cramer Remix: In all my years, never seen this! Mar 30 2015
    3 (Rough) Dates Exelixis Shareholders Need to Know Mar 30 2015
    Biotech in nice uptrend: Adami Mar 25 2015
    Is Exelixis (EXEL) Stock a Solid Choice Right Now? - Tale of the Tape Mar 18 2015
    EXELIXIS, INC. Financials Mar 10 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK